Drug or treatment

Talquetamab clinical trials

• 15Clinical trials
• 26Countries

Newest trials

All recruiting trials (15)

• Infliximab to Help Prevent CRS During Teclistamab or Talquetamab Therapy in Relapsed/Refractory Myeloma

  This phase 2 trial tests whether infliximab can prevent cytokine release syndrome in patients with relapsed or refractory multiple myeloma who are being treated with teclistamab or talquetamab.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07657312

• Daratumumab combined with teclistamab or talquetamab for frail adults with newly diagnosed multiple myeloma

  This study will test whether adding teclistamab or talquetamab to daratumumab helps frail adults newly diagnosed with multiple myeloma remain progression-free at 18 months.

  Recruiting at 6 sites Phase 2 European Myeloma Network B.V. · Ascoli Piceno and 28 other locations · NCT07107529

• Talquetamab bridging therapy followed by ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

  This trial tests whether giving talquetamab as a temporary bridging treatment before cilta‑cel is safe and feasible for people with relapsed or refractory multiple myeloma who plan to receive CAR‑T therapy.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT07093554

• Mezigdomide plus talquetamab for relapsed and refractory multiple myeloma

  This phase 1 test tries combining mezigdomide with talquetamab and dexamethasone in adults with relapsed and refractory multiple myeloma who have had at least three prior therapies to find a safe dose and see if it helps.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT07032714

• Talquetamab treatment for elderly patients with early relapse multiple myeloma

  This study is testing if a new treatment called Talquetamab can help older patients with early relapse multiple myeloma who can't tolerate stronger therapies feel better and have a safer option.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT06827860

• Using bispecific T-cell redirectors for first-line treatment in transplant-eligible multiple myeloma patients

  This study is testing if a new combination of treatments can help newly diagnosed multiple myeloma patients who are eligible for a stem cell transplant feel better and improve their outcomes.

  Recruiting Phase 2 North Estonia Medical Centre · Copenhagen and 6 other locations · NCT06505369

• Assessing the effectiveness of teclistamab for multiple myeloma

  This study is testing if teclistamab can help people with relapsed or hard-to-treat multiple myeloma who have already tried at least three other treatments.

  Recruiting at 16 sites Universitaire Ziekenhuizen KU Leuven · Bonheiden, Antwerpen and 16 other locations · NCT06477783

• Talquetamab plus lenalidomide for maintenance after autologous stem cell transplant in multiple myeloma

  Researchers will test whether adding talquetamab to lenalidomide after an autologous stem cell transplant helps people with multiple myeloma stay in remission.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT06461988

• Talquetamab combined with iberdomide and dexamethasone for relapsed or refractory multiple myeloma

  This phase 1 trial will test whether adding iberdomide and dexamethasone to talquetamab helps people with relapsed or refractory multiple myeloma who have already received proteasome inhibitors, immunomodulatory drugs, and CD38 antibodies.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT06348108

• Combination treatment for high-risk smoldering multiple myeloma

  This study is testing two different combination treatments to see which one helps people with high-risk smoldering multiple myeloma delay their disease from getting worse.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06100237

• Talquetamab treatment for multiple myeloma after BCMA CAR T-cell therapy

  This study is testing if talquetamab can help people with multiple myeloma who haven't improved after receiving BCMA CAR T-cell therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06066346

• Outpatient treatment for multiple myeloma using teclistamab or talquetamab

  This study is testing if two new treatments, teclistamab and talquetamab, can safely help adults with relapsed or hard-to-treat multiple myeloma when given as outpatient care.

  Recruiting at 16 sites Phase 2 SCRI Development Innovations, LLC · Tucson, Arizona and 16 other locations · NCT05972135

• Combination treatment for newly diagnosed multiple myeloma patients

  This study is testing a new combination treatment for people with newly diagnosed multiple myeloma to see if it can be a safer and more effective alternative to traditional high-dose therapy and stem cell transplants.

  Recruiting at 11 sites Phase 2 University of Heidelberg Medical Center · Berlin and 10 other locations · NCT05695508

• Combining teclistamab and talquetamab with daratumumab and lenalidomide for newly diagnosed multiple myeloma

  This study is testing two new treatment combinations for people with newly diagnosed multiple myeloma to see if they work better than the standard treatment.

  Recruiting at 66 sites Phase 3 Janssen Research & Development, LLC · Gilbert, Arizona and 269 other locations · NCT05552222

• Evaluating talquetamab for patients with relapsed or refractory multiple myeloma

  This study is testing a new drug called talquetamab to see if it can help people with relapsed or refractory multiple myeloma feel better and manage their disease.

  Recruiting at 14 sites Phase 2 Janssen Research & Development, LLC · Birmingham, Alabama and 77 other locations · NCT04634552

Quick answers

How many clinical trials of Talquetamab are recruiting right now?

15, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 26 countries. The most sites are in United States (11 trials), Germany (3 trials), Belgium (3 trials), Netherlands (3 trials), Spain (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 10, Phase 1: 3, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →